Article

Lecia V. Sequist on Side Effects From Agents for Resistant Lung Cancer

Author(s):

Lecia V. Sequist

Lecia V. Sequist, discusses the adverse event profiles of rociletinib (CO-1686) and osimertinib (AZD9291).

Lecia V. Sequist, associate professor of medicine, Massachusetts General Hospital, discusses the adverse event profiles of rociletinib (CO-1686) and osimertinib (AZD9291), two agents specific to acquired T790M mutations in EGFR-positive non-small cell lung cancer (NSCLC).

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Minimally Invasive Surgery Transforms Lung Cancer Recovery
Image of man with text.
Image of woman with text.
Unlike most GI cancers, GIST starts in supportive stromal tissue, not surface cells, and is classified as a sarcoma, says Dr. Weijing Sun.
Six-time cancer survivor Staci Kirk urges patients to trust their bodies and speak up to ensure their needs are understood and addressed throughout cancer care.
Certain treatments may accelerate aging in survivors, but tailored care and healthy habits can help reduce long-term risks, researchers said.
Image of man with text.
Image of woman with text.
Image of man with text.
Image of Staci.
Related Content
CURE spoke with a thoracic surgeon about the impact of minimally invasive surgery for patients.
August 1st 2025

How Robotic Surgery Can Impact Outcomes For Those With Lung Cancer

Alex Biese
CURE spoke with a thoracic surgeon about the impact of minimally invasive surgery for patients.
CURE Cancer Horizons logo
August 1st 2025

FDA Approvals from February 2024

Alex Biese Brielle Benyon
February brought in multiple FDA approvals in the oncology space. Here’s an overview of some of the most recent ones.
The FDA awarded orphan drug designation to VT3989 for mesothelioma: © stock.adobe.com.
August 1st 2025

FDA Grants Orphan Drug Status to VT3989 for Mesothelioma Treatment

Spencer Feldman
The FDA awarded orphan drug designation to VT3989 for mesothelioma, supporting the experimental cancer treatment’s development.
Guidelines for Childhood Neuroblastoma, FDA Decisions and More
August 1st 2025

Guidelines for Childhood Neuroblastoma, FDA Decisions and More

Alex Biese Brielle Benyon
Last week, we saw a few moving parts in the regulatory space, from new NCCN guidelines for pediatric neuroblastoma treatment to FDA Fast Tracks and Priority Reviews
Image of clinical trial.
August 1st 2025

New Trials Advance Treatments for Lymphoma, Lung Cancer and Sarcomas

Spencer Feldman
New clinical trials are advancing treatments for cutaneous T-cell lymphoma, advanced solid tumors, pediatric sarcomas and ALK-positive lung cancer.
The FDA granted fast track status to DB-1310 for advanced nonsquamous NSCLC: © stock.adobe.com.
August 1st 2025

FDA Fast Tracks DB-1310 for Advanced Nonsquamous Lung Cancer

Spencer Feldman
The FDA granted fast track status to DB-1310, a HER3-targeting antibody-drug conjugate, for advanced nonsquamous non-small cell lung cancer.